Estradiol 17β and Its Metabolites Stimulate Cell Proliferation and Antagonize Ascorbic Acid-Suppressed Cell Proliferation in Human Ovarian Cancer Cells
Restricted accessResearch articleFirst published online January, 2014
Estradiol 17β and Its Metabolites Stimulate Cell Proliferation and Antagonize Ascorbic Acid-Suppressed Cell Proliferation in Human Ovarian Cancer Cells
Estradiol 17β (E2β) and ascorbic acid (AA) have been implicated in cancer progression. However, little is known about the actions of biologically active metabolites of E2β, 2-hydroxyestradiol (2OHE2), 4-hydroxyestradiol (4OHE2), 2-methoxyestradiol (2ME2), and 4-methoxyestradiol (4ME2) synthesized sequentially by cytochrome P450, family 1, subfamily A (CYP1A1) and B (CYP1B1), polypeptide 1, and catechol-O-methyltransferase (COMT) on ovarian cancer. Herein, we examined the expression of CYP1A1, CYP1B1, COMT, and estrogen receptor α (ERα) and β (ERβ) in human ovarian surface epithelial (IOSE-385) and cancer cell lines (OVCAR-3, SKOV-3, and OVCA-432). We also investigated the roles of E2β, 2OHE2, 4OHE2, 2ME2, and 4ME2 in cell proliferation, and their interactive effects with AA on ovarian cells. We found the expression of CYP1A1, CYP1B1, COMT, ERα, and ERβ in most cell lines tested. Treating cells with physiological concentrations of E2β and its metabolites promoted (13%-42% of the control) IOSE-385 and OVCAR-3 proliferation. The ER blockade inhibited IOSE-385 (∼76%) and OVCAR-3 (∼87%) proliferative response to E2β but not to its metabolites. The ERα blockade inhibited (∼85%) E2β-stimulated OVCAR-3 proliferation, whereas ERβ blockade attenuated (∼83%) E2β-stimulated IOSE-385 proliferation. The AA at ≥250 μmol/L completely inhibited serum-stimulated cell proliferation in all cell lines tested; however, such inhibition in IOSE-385, OVCAR-3, and OVCA-432 was partially (∼10%-20%) countered by E2β and its metabolites. Thus, our findings indicate that E2β and its metabolites promote cell proliferation and antagonize the AA-suppressed cell proliferation in a subset of ovarian cancer cells, suggesting that blocking the actions of E2β and its metabolites may enhance AA’s antiovarian cancer activity.
SantenRJLeszczynskiDTilson-MalletNEnzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways. Ann N Y Acad Sci. 1986;464:126–137.
6.
HobkirkR. Steroid sulfotransferases and steroid sulfate sulfatases: characteristics and biological roles. Can J Biochem Cell Biol. 1985;63(11):1127–1144.
7.
BallPKnuppenR. Formation, metabolism, and physiologic importance of catecholestrogens. Am J Obstet Gynecol. 1990;163(6 pt 2):2163–2170.
XuXRomanJMIssaqHJKeeferLKVeenstraTDZieglerRG. Quantitative measurement of endogenous estrogens and estrogen metabolites in human serum by liquid chromatography-tandem mass spectrometry. Anal Chem. 2007;79(20):7813–7821.
10.
BergDThalerFKussE. Concentrations of 2-hydroxyoestrogens in human sera measured by a heterologous immunoassay with an 125I-labelled ligand. Acta Endocrinol (Copenh). 1982;100(1):154–160.
11.
BergDSonsallaRKussE. Concentrations of 2-methoxyoestrogens in human serum measured by a heterologous immunoassay with an 125I-labelled ligand. Acta Endocrinol (Copenh). 1983;103(2):282–288.
12.
LakhaniNJVenitzJFiggWDSparreboomA. Pharmacogenetics of estrogen metabolism and transport in relation to cancer. Curr Drug Metab. 2003;4(6):505–513.
13.
SeegerHMueckAO. The effect of estradiol metabolites and progestogens on the proliferation of human ovarian cancer cells. Panminerva Med. 2006;48(1):13–17.
14.
MueckAO, Seeger H. 2-Methoxyestradiol-biology and mechanism of action. Steroids. 2010;75(10):625–631.
15.
SeegerHWallwienerDKraemerEMueckAO. Estradiol metabolites are potent mitogenic substances for human ovarian cancer cells. Eur J Gynaecol Oncol. 2005;26(4):383–385.
16.
CushmanMHeHMKatzenellenbogenJALinCMHamelE. Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, anendogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. J Med Chem. 1995;38(12):2041–2049.
17.
KatoSSadaranganiA, Lange S, et al. 2-methoxyestradiol mediates apoptosis through caspase-dependent and independent mechanisms in ovarian cancer cells but not in normal counterparts. Reprod Sci. 2008;15(9):878–894.
18.
CameronEPaulingL.Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA. 1976;73(10):3685–3689.
19.
LevineMPadayattySJEspeyMG. Vitamin C: a concentration–function approach yields pharmacology and therapeutic discoveries. Adv Nutr. 2011;2(2):78–88.
20.
MamedeACTavaresSDAbrantesAMTrindadeJMaiaJMBotelhoMF. The role of vitamins in cancer: a review. Nutr Cancer. 2011;63(4):479–494.
21.
ChenQEspeyMGKrishnaMCPharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA. 2005;102(38):13604–13609.
22.
ChenQEspeyMGSunAYPharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA. 2008;105(32):11105–11109.
23.
ChenQEspeyMGSunAYAscorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci USA. 2007;104(21):8749–8754.
24.
BastRCJrFeeneyMLazarusHNadlerLMColvinRBKnappRC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68(5):1331–1337.
25.
HagopianGSMillsGBKhokharARBastRCJrSiddikZH. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane) (trans-diacetato) (dichloro)-platinum (IV). Clin Cancer Res. 1999;5(3):655–663.
26.
LauKMMokSCHoSM. Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci USA. 1999;96(10):5722–5727.
27.
JobeSORamadossJKochJMJiangYZhengJMagnessRR. Estradiol-17beta and its cytochrome P450- and catechol-O-methyltransferase-derived metabolites stimulate proliferation in uterine artery endothelial cells: role of estrogen receptor-alpha versus estrogen receptor-beta. Hypertension. 2010;55(4):1005–1011.
28.
DaiCJiangYLiYWangKLiuPPatankarMSZhengJ. Expression and roles of Slit/Robo in human ovarian cancer. Histochem Cell Biol. 2011;135(5):475–485.
29.
ZhengJWenYSongYWangKChenDBMagnessRR. Activation of multiple signaling pathways is critical for fibroblast growth factor 2- and vascular endothelial growth factor-stimulated ovine fetoplacental endothelial cell proliferation. Biol Reprod. 2008;78(1):143–150.
30.
CameronEPaulingL. Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA. 1978;75(9):4538–4542.
31.
MurrayGL. The role of cytochrome P450 in tumour development and progression and its potential in therapy. J Pathol. 2000;192(4):419–426.
32.
LeungYKLauKMMobleyJJiangZHoSM. Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: alternative subcellular enzyme compartmentation may contribute to carcinogenesis. Cancer Res. 2005;65(9):3726–3734.
33.
MurdochWJVan KirkEA. Oestradiol inhibits spontaneous and cisplatin-induced apoptosis in epithelial ovarian cancer cells: relationship to DNA repair capacity. Apoptosis. 1997;2(5):478–484.
34.
BaiWOliveros-SaundersBWangQAcevedo-DuncanMENicosiaSV. Estrogen stimulation of ovarian surface epithelial cell proliferation. In Vitro Cell Dev Biol Anim. 2000;36(10):657–666.
35.
ChoiKCKangSKTaiCJAuerspergNLeungPC. Estradiol up-regulates antiapoptotic Bcl-2 messenger ribonucleic acid and protein in tumorigenic ovarian surface epithelium cells. Endocrinology. 2001;142(6):2351–2360.
36.
SyedVUlinskiGMokSCYiuGKHoSM. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res. 2001;61(18):6768–6776.
37.
SongJFadielAEdusaVEstradiol-induced ezrin overexpression in ovarian cancer: a new signaling domain for estrogen. Cancer Lett. 2005;220(1):57–65.
38.
ClementPB. Histology of the ovary. Am J Surg Pathol. 1987;11(4):277–303.
39.
CarrBR. The ovary. In: BruceRCarrBRBlackwellRE, eds. Textbook of Reproductive Medicine. Norwalk, CT: Appleton and Lange; 1993:183–207.
40.
BechtelMKBonavidaB. Inhibitory effects of 17beta-estradiol and progesterone on ovarian carcinoma cell proliferation: a potential role for inducible nitric oxide synthase. Gynecol Oncol. 2001;82(1):127–138.
41.
WrightJMStoufferRLRodlandKD. Estrogen inhibits cell cycle progression and retinoblastoma phosphorylation in rhesus ovarian surface epithelial cell culture. Mol Cell Endocrinol. 2003;208(1-2):1–10.
42.
WrightJWStoufferRLRodlandKD. High-dose estrogen and clinical selective estrogen receptor modulators induce growth arrest, p21, and p53 in primate ovarian surface epithelial cells. J Clin Endocrinol Metab. 2005;90(6):3688–3695.
43.
YapOWBhatGLiuLTollefsbolTO. Epigenetic modifications of the estrogen receptor beta gene in epithelial ovarian cancer cells. Anticancer Res. 2009;29(1):139–144.
44.
GaoNNesterRA, Sarkar MA. 4-Hydroxy estradiol but not 2-hydroxy estradiol induces expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor A through phosphatidylinositol 3-kinase/Akt/FRAP pathway in OVCAR-3 and A2780-CP70 human ovarian carcinoma cells. Toxicol Appl Pharmacol. 2004;196(1):124–135.
45.
MooberrySL. Mechanism of action of 2-methoxyestradiol: new developments. Drug Resist Updat. 2003;6(6):355–361.
46.
BologaCGRevankarCMYoungSMVirtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol. 2006;2(4):207–212.
47.
HenicENoskovaVHøyer-HansenGHanssonSCasslénB. Estradiol attenuates EGF-induced rapid uPAR mobilization and cell migration via the G-protein-coupled receptor 30 in ovarian cancer cells. Int J Gynecol Cancer. 2009;19(2):214–222.
48.
TangMSubbiahMT. Estrogens protect against hydrogen peroxide and arachidonic acid induced DNA damage. Biochim Biophys Acta. 1996:1299(2):155–159.
49.
BokovAFKoDRichardsonA. The effect of gonadectomy and estradiol on sensitivity to oxidative stress. Endocr Res. 2009;34(1-2):43–58.
